CN111683665A - 用于微生物群调节的人乳寡糖及其合成组合物 - Google Patents

用于微生物群调节的人乳寡糖及其合成组合物 Download PDF

Info

Publication number
CN111683665A
CN111683665A CN201880088085.XA CN201880088085A CN111683665A CN 111683665 A CN111683665 A CN 111683665A CN 201880088085 A CN201880088085 A CN 201880088085A CN 111683665 A CN111683665 A CN 111683665A
Authority
CN
China
Prior art keywords
human
hmo
akkermansia
abundance
human milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880088085.XA
Other languages
English (en)
Chinese (zh)
Inventor
L·K·比格斯奈斯
B·麦康奈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom AS filed Critical Glycom AS
Publication of CN111683665A publication Critical patent/CN111683665A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201880088085.XA 2017-11-30 2018-11-30 用于微生物群调节的人乳寡糖及其合成组合物 Pending CN111683665A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (1)

Publication Number Publication Date
CN111683665A true CN111683665A (zh) 2020-09-18

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880088085.XA Pending CN111683665A (zh) 2017-11-30 2018-11-30 用于微生物群调节的人乳寡糖及其合成组合物

Country Status (7)

Country Link
US (1) US20200323921A1 (https=)
EP (1) EP3716983A4 (https=)
JP (1) JP2021504420A (https=)
KR (1) KR102741265B1 (https=)
CN (1) CN111683665A (https=)
BR (1) BR112020010843A2 (https=)
WO (1) WO2019106620A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
CN113194960A (zh) 2018-12-19 2021-07-30 格礼卡姆股份公司 用于治疗使用低fodmap饮食的人的组合物和方法
EP3897663A4 (en) * 2018-12-21 2022-09-07 Glycom A/S COMPOSITION AND METHOD FOR PROMOTING HEALING OF THE INTESTINAL BARRIER
KR20220017988A (ko) * 2019-06-05 2022-02-14 글리콤 에이/에스 비-셀리악 밀 및/또는 글루텐 민감성을 앓고 있는 환자에서 증상 치료에 사용하기 위한 모유 올리고사카라이드
JP2022548785A (ja) * 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
CA3178744C (en) 2020-05-13 2023-11-14 Ardythe L. Morrow Fucosylated oligosaccharides for prevention of coronavirus infection
WO2021231750A1 (en) * 2020-05-13 2021-11-18 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
EP4188391A1 (en) * 2020-07-31 2023-06-07 Abbott Laboratories Method of preventing, reducing or delaying fatty liver disease
CN116490079A (zh) * 2020-12-04 2023-07-25 雀巢产品有限公司 用于在个体中使用以支持夜间睡眠持续时间的包含人乳低聚糖的组合物
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201380A (zh) * 2010-10-11 2013-07-10 詹尼温生物技术有限责任公司 新岩藻糖基转移酶及它们的应用
CN104918626A (zh) * 2012-11-19 2015-09-16 卢万天主教大学 阿克曼氏菌属用于治疗代谢病症的用途
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US20160367577A1 (en) * 2014-12-08 2016-12-22 Glycom A/S Synthetic composition for treating metabolic disorders
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
ES2651067T3 (es) * 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
PT2672844E (pt) * 2011-02-10 2015-02-04 Nestec Sa Modulação do crescimento de bifidobactérias utilizando uma combinação de oligossacáridos identificados no leite humano
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
HK1199607A1 (en) * 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
WO2013161820A1 (ja) * 2012-04-23 2013-10-31 国立大学法人京都大学 ビフィズス菌の増殖促進用組成物
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
US20160120915A1 (en) * 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
PL3209673T5 (pl) * 2014-10-24 2023-10-23 Glycom A/S Mieszaniny hmo
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
CN107404925A (zh) * 2015-03-05 2017-11-28 雀巢产品技术援助有限公司 用于预防或治疗婴儿或幼儿胃肠感染/炎症的组合物
CN108367031A (zh) * 2015-10-05 2018-08-03 瑞士达沃斯高山气候和医学研究院 嗜黏蛋白阿克曼氏菌用于治疗炎症病况的用途
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
RU2744199C2 (ru) * 2016-01-26 2021-03-03 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигосахариды грудного молока, применяемая для младенцев или детей младшего возраста в целях профилактики или лечения аллергических реакций
WO2018157900A1 (en) * 2017-03-01 2018-09-07 Glycom A/S Synthetic composition for microbiota modulation
EP3634429A4 (en) * 2017-05-09 2020-11-04 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201380A (zh) * 2010-10-11 2013-07-10 詹尼温生物技术有限责任公司 新岩藻糖基转移酶及它们的应用
CN104918626A (zh) * 2012-11-19 2015-09-16 卢万天主教大学 阿克曼氏菌属用于治疗代谢病症的用途
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US20160367577A1 (en) * 2014-12-08 2016-12-22 Glycom A/S Synthetic composition for treating metabolic disorders
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREW J. TARR，等: "The prebiotics 3′Sialyllactose and 6′Sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: Evidence for effects on the gut-brain axis" *
HIPPE B，等，: "Abundance and diversity of GI microbiota rather than IgG4 levels correlate with abdominal inconvenience and gut permeability in consumers claiming food intolerances" *
LV WANG，等: "Low Relative Abundances of the Mucolytic Bacterium Akkermansia muciniphila and Bifidobacterium spp. in Feces of Children with Autism" *
冯泽猛，等: "胃肠道黏液层中Akkermansia muciniphila的定殖及其与宿主的相互作用" *
李世芳，等: "动物肠道菌群的研究进展" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途

Also Published As

Publication number Publication date
WO2019106620A1 (en) 2019-06-06
US20200323921A1 (en) 2020-10-15
EP3716983A1 (en) 2020-10-07
KR102741265B1 (ko) 2024-12-11
JP2021504420A (ja) 2021-02-15
EP3716983A4 (en) 2022-03-02
KR20200091438A (ko) 2020-07-30
BR112020010843A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
US11696921B2 (en) Synthetic composition for microbiota modulation
KR102741265B1 (ko) 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
US11529365B2 (en) Synthetic composition for microbiota modulation
US11291677B2 (en) Synthetic composition for microbiota modulation
US11278558B2 (en) Synthetic composition for microbiota modulation
CN108348536B (zh) 治疗抗生素相关性并发症的合成组合物
CN108541221A (zh) Hmo的混合物
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
JP2023501111A (ja) 腸管における胆汁酸プロファイルを均衡させるための合成組成物
US11554131B2 (en) Mixture of HMOs for treating autoimmune diseases
US10835544B2 (en) Synthetic composition for regulating satiety
JP2022513524A (ja) 低ｆｏｄｍａｐ食を使用してヒトを治療するための組成物および方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination